Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 29;23(19):11502.
doi: 10.3390/ijms231911502.

miRNA: A Promising Therapeutic Target in Cancer

Amrutha Menon  1 , Noraini Abd-Aziz  2 , Kanwal Khalid  2 , Chit Laa Poh  2 , Rakesh Naidu  3
Affiliations
Review

miRNA: A Promising Therapeutic Target in Cancer

Amrutha Menon et al. Int J Mol Sci. .

Abstract

microRNAs are small non-coding RNAs that regulate several genes post-transcriptionally by complementarity pairing. Since discovery, they have been reported to be involved in a variety of biological functions and pathologies including cancer. In cancer, they can act as a tumor suppressor or oncomiR depending on the cell type. Studies have shown that miRNA-based therapy, either by inhibiting an oncomiR or by inducing a tumor suppressor, is effective in cancer treatment. This review focusses on the role of miRNA in cancer, therapeutic approaches with miRNAs and how they can be effectively delivered into a system. We have also summarized the patents and clinical trials in progress for miRNA therapy.

Keywords: cancer; miRNA; miRNA delivery; oncomiR; therapy; tumor suppressor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Different hallmarks of cancer being induced or inhibited by various miRNAs.
Figure 2
Figure 2
Different miRNAs regulating various cancers. One type of cancer is being regulated by mutliple miRNAs. A single miRNA can act as a tumor suppressor or oncomiR based on the cell type.
Figure 3
Figure 3
miRNA-based therapeutic strategies against cancer. (A). Several strategies are employed to repress the expression of oncomiRs and to promote the activity of tumor suppressor miRNAs. (B). miRNA-based therapeutic strategies and their mechanism of action against cancer. The effect of oncomiRs on tumor-suppressing mRNA (TS mRNA) can be controlled by (a) anti-miR oligos, (b) Locked Nucleic Acid (LNA), (c) miRNA sponges and (d) miRNA masking.
Figure 4
Figure 4
Different systems available for miRNA delivery can be categorized into non-viral vectors and viral vectors. The non-viral miRNA delivery system uses organic [161,162], inorganic [163] or polymer-based carriers [164,165], whereas viral-based delivery system uses lentiviruses [166,167,168], retroviruses [169], adenoviruses or adeno-associated viruses (AAV) [170].
Figure 5
Figure 5
The cellular uptake of miRNA-loaded exosomes. Purified exosomes were transfected with the miRNA mimic to form miRNA-loaded exosomes which may enter cells through fusion or endocytosis, where they bind to target mRNA in the cytosol.
See this image and copyright information in PMC

References

    1. Bartel D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. doi: 10.1016/S0092-8674(04)00045-5. - DOI - PubMed
    1. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854. doi: 10.1016/0092-8674(93)90529-Y. - DOI - PubMed
    1. Lindsay M.A., Griffiths-Jones S., Dalmay T. Mechanism of miRNA-mediated repression of mRNA translation. Essays Biochem. 2013;54:29–38. doi: 10.1042/bse0540029. - DOI - PubMed
    1. Zou Y., Chiu H., Domenger D., Chuang C.-F., Chang C. The lin-4 microRNA targets the LIN-14 transcription factor to inhibit netrin-mediated axon attraction. Sci. Signal. 2012;5:ra43. doi: 10.1126/scisignal.2002437. - DOI - PMC - PubMed
    1. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136:642–655. doi: 10.1016/j.cell.2009.01.035. - DOI - PMC - PubMed